Stock fact sheet · data as of
AnaptysBio, Inc. (ANAB): fair value, margin of safety and Wheel Score
Healthcare · Biotechnology · United States · High Growth
Is ANAB undervalued?
ANAB has a margin of safety of 59%: the stock closed at 48.71 on 16 Oct 2026 against a GLS average fair value of 119.69. 4 of the 7 valuation models that produced a number sit above the price. Our screens treat a discount this large as a strong starting point for a cash-secured put, not as a verdict - the fair value is a model output, and a wide gap can mean the models are missing something the market knows.
The 7 models disagree widely: Graham Number gives 7.38 while GLS Growth gives 409.45. A spread that wide means the average is sensitive to which methods you trust; the model table below shows where each one lands, and the Quote page lets you switch any of them off.
The nightly engine files ANAB under High Growth: revenue and earnings growing fast enough that the growth-based models carry the valuation.
Nine valuation models for ANAB
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | 7.38 | -85% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 223.75 | +359% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 85.99 | +77% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 409.45 | +741% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | 12.46 | -74% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | 24.45 | -50% | Eight years of compounded free cash flow: the price at which the business pays for itself |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 74.31 | +53% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | 0.7715 | -98% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 79.17 | +63% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Financial health is average - ANAB passes 5 of the nine Piotroski tests, which falls one point short of the Sunday Scan's "6 or more" rule. The Financials tab on the Quote page shows which tests fail. The GLS Moat score is low at 2.7 out of 10, which says the ten-year record of revenue, earnings, margins and returns on capital has been inconsistent - growth and shocks rather than steady compounding.
Returns on capital are thin or negative - ROIC -25.8%, ROE -35.6%, ROA -3.6% - with debt at 0.38 times equity and a free-cash-flow yield of 1.2%.
AnaptysBio, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Research and Development 100% (quarter Q3 FY2025).
Institutional ownership scores 10/10, insider activity 1/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 5 / 9 | ROIC | -25.8% |
|---|---|---|---|
| GLS Moat | 2.7 / 10 | ROE | -35.6% |
| Debt / equity | 0.38 | ROA | -3.6% |
| Free-cash-flow yield | 1.2% | Payout ratio | 0% |
| Institutions | 10 / 10 | Insiders · Congress | 1 · 5 / 10 |
Wheel Score 66: Good
ANAB scores 66 out of 100 on the Wheel Score (Good band, 65-79). The score blends the margin of safety (Value, 25/25), Piotroski health (11/20), the GLS moat (4/15), the option premium on offer (14/20) and how easily the stock trades (12/20). Moat (4/15) is the part holding the score back.
Implied volatility is 85% on the near-the-money contracts 20-60 days out - above the 60% ceiling of the sweet spot. Premiums are large, but the Wheel Score tapers the Premium points (14 of 20) because volatility this high usually comes with a reason. Chain open interest is 3,604 contracts across all expiries - enough for the wheel at normal size.
Volume runs at 416k shares a day on a market cap of $1.5B, with a beta of 0.41 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 12 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 25 / 25 | 59% margin of safety | |
| Health | 11 / 20 | Piotroski 5/9 | |
| Moat | 4 / 15 | moat 2.7/10 | |
| Premium | 14 / 20 | implied volatility 85% | |
| Stability | 12 / 20 | 416k shares/day, $1.5B cap, beta 0.41 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 3 Nov 2026 (after the close), 18 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Biotechnology
The 12 companies below are the closest to AnaptysBio, Inc. by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| QURE uniQure N.V. | 20.97 | - | - | 45Weak | $1.5B |
| RARE Ultragenyx Pharmaceutical Inc. | 14.90 | - | - | 45Weak | $1.5B |
| IMCR Immunocore Holdings plc | 29.48 | - | - | 45Weak | $1.5B |
| STOK Stoke Therapeutics, Inc. | 23.26 | - | - | 45Weak | $1.5B |
| INVA Innoviva, Inc. | 20.86 | 54.26 | +62% | 77Good | $1.5B |
| KLRA Kailera Therapeutics, Inc. | 11.71 | 1.23 | -852% | 26Weak | $1.5B |
| COAG Hemab Therapeutics Holdings, Inc. Common Stock | 32.52 | 3.06 | -962% | 11No options | $1.5B |
| ABSI Absci Corporation | 8.88 | 0.0424 | -20862% | 31Weak | $1.5B |
| MAZE Maze Therapeutics, Inc. | 27.48 | 3.82 | -618% | 35Weak | $1.5B |
| AAPG Ascentage Pharma Group International | 14.69 | - | - | 27No options | $1.4B |
| OMER Omeros Corporation | 18.79 | 66.86 | +72% | 64Fair | $1.4B |
| RAPP Rapport Therapeutics, Inc. Common Stock | 28.33 | 0.7949 | -3464% | 23Weak | $1.4B |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about ANAB
Is ANAB undervalued right now?
By the GLS models, yes: at 48.71 the stock is 59% below the average fair value of 119.69 (data as of 16 Oct 2026). Whether the discount is deserved is the question to research next.
What is the Wheel Score of ANAB and what does it mean?
ANAB scores 66 out of 100 (Good). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.
What is the GLS fair value for ANAB?
119.69 per share as of 16 Oct 2026 - the simple average of the 7 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does AnaptysBio, Inc. report earnings next?
The next earnings report is due on 3 Nov 2026 (after the close), 18 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does ANAB have listed options, and how liquid are they?
Yes. The nightly snapshot found 156 listed contracts with 3,604 open interest across all expiries and implied volatility of 85% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.